Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Ezetimibe with statins].

Christel Jublanc1, Philippe Giral, Gérard Turpin

  • 1Service d'Endocrinologie Métabolisme, Groupe Hospitalier Pitié Salpêtrière, Paris. christel.jublanc@psl.ap-hop-paris.fr

Presse Medicale (Paris, France : 1983)
|March 22, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ACTH-dependent Cushing's syndrome in MEN1: When multiple tumors complicate the diagnosis.

Annales d'endocrinologie·2026
Same author

Advancing Retinal Imaging for Cardiovascular Risk Assessment.

JAMA cardiology·2026
Same author

Regulation of HDL dysfunctionality by phosphatidylethanolamine links poly-unsaturated fatty acids with atherosclerotic cardiovascular diseases.

Molecular metabolism·2025
Same author

Inquiry Regarding Body Temperature Data in HuMAIN-HFpEF Trial.

JAMA cardiology·2025
Same author

Cardiometabolic risk in pseudohypertriglyceridemia resulting from hyperglycerolemia.

Journal of clinical lipidology·2025
Same author

Enhancing Cardiovascular Risk Prediction with a Simplified Carotid IMT Protocol: Evidence from the IMPROVE Study.

Biomedicines·2025
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Ezetimibe, a cholesterol absorption inhibitor, effectively lowers LDL cholesterol when added to statin therapy. It offers a valuable option for patients not reaching lipid targets or those intolerant to statins.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Context:

  • Cholesterol management is crucial for cardiovascular health.
  • Statins are primary agents for lowering low-density lipoprotein (LDL) cholesterol.
  • Novel therapeutic strategies are needed for patients with hypercholesterolemia.

Purpose:

  • To evaluate the efficacy and tolerability of ezetimibe as a cholesterol absorption inhibitor.
  • To assess the benefits of combining ezetimibe with statin therapy.
  • To identify patient populations that may benefit from ezetimibe treatment.

Summary:

  • Ezetimibe is a novel drug class that inhibits intestinal cholesterol absorption.
  • Clinical studies demonstrate that adding ezetimibe (10 mg/d) to statin therapy can further reduce LDL cholesterol by up to 20%.

Related Experiment Videos

  • Ezetimibe is well-tolerated and can be used as monotherapy in statin-intolerant patients.

    • Impact:

    • Ezetimibe provides an effective complementary mechanism to statins for cholesterol reduction.
    • It expands treatment options for patients who cannot achieve LDL cholesterol goals with diet and statins alone.
    • The drug offers a safe alternative for individuals with statin intolerance, improving lipid management and potentially cardiovascular outcomes.